These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11747720)

  • 1. Advanced age a risk factor for illness temporally associated with yellow fever vaccination.
    Martin M; Weld LH; Tsai TF; Mootrey GT; Chen RT; Niu M; Cetron MS;
    Emerg Infect Dis; 2001; 7(6):945-951. PubMed ID: 11747720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events following yellow fever vaccination in immunocompromised persons.
    Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
    Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
    Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related risk of adverse events following yellow fever vaccination in Australia.
    Lawrence GL; Burgess MA; Kass RB
    Commun Dis Intell Q Rep; 2004; 28(2):244-8. PubMed ID: 15460963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
    Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
    Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.
    Khromava AY; Eidex RB; Weld LH; Kohl KS; Bradshaw RD; Chen RT; Cetron MS;
    Vaccine; 2005 May; 23(25):3256-63. PubMed ID: 15837230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina.
    Ripoll C; Ponce A; Wilson MM; Sharif N; Vides JB; Armoni J; Teuwen DE
    Hum Vaccin; 2008; 4(2):121-6. PubMed ID: 18382132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliminating yellow fever epidemics in Africa: Vaccine demand forecast and impact modelling.
    Jean K; Hamlet A; Benzler J; Cibrelus L; Gaythorpe KAM; Sall A; Ferguson NM; Garske T
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008304. PubMed ID: 32379756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of yellow fever in persons traveling to the tropics.
    Monath TP; Cetron MS
    Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An unusual case of influenza-like illness after yellow fever vaccination.
    Lamson DM; Ramani R; Kleabonas M; Metcalfe M; Humphrey C; St George K
    J Clin Virol; 2014 May; 60(1):67-9. PubMed ID: 24594082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
    Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
    J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.